Zanubrutinib, lenalidomide, rituximab, temozolomide ㊣ methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial
Jia Song 1 2, Huijuan Jiang 1 2, Kai Ding 1 2, Hui Liu 1 2, Yihao Wang 1 2, Shan Gao 1 2, Yue Ren 1 2, Zhaoyun Liu 1 2, Jie Zhuo 3, Bing Li 3, Guokai Wang 3, Zongjiu Jiao 4, Da Gao 5, Rong Fu 1 2
- PMID: 41582824
- DOI: 10.1111/bjh.70335
Song J, Jiang H, Ding K, Liu H, Wang Y, Gao S, Ren Y, Liu Z, Zhuo J, Li B, Wang G, Jiao Z, Gao D, Fu R. Zanubrutinib, lenalidomide, rituximab, temozolomide ㊣ methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial. Br J Haematol. 2026 Apr;208(4):1424-1428.
|
10
Configuring a Robust Sulfur命ich Shielding Interphase for Suppressing Electric咄ield呻riven Zinc Corrosion
